Q1 EPS Estimate for Jazz Pharmaceuticals Lifted by Analyst

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Investment analysts at Zacks Research raised their Q1 2027 earnings per share (EPS) estimates for shares of Jazz Pharmaceuticals in a research report issued to clients and investors on Monday, February 2nd. Zacks Research analyst Team now anticipates that the specialty pharmaceutical company will post earnings per share of $3.82 for the quarter, up from their previous estimate of $3.80. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $16.96 per share.

Other equities research analysts also recently issued research reports about the stock. Bank of America lifted their price target on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. JPMorgan Chase & Co. dropped their target price on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research report on Monday, October 27th. Piper Sandler reissued an “overweight” rating and set a $219.00 price target (up previously from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th. Finally, Truist Financial increased their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Fourteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $205.67.

Jazz Pharmaceuticals Trading Up 1.7%

NASDAQ JAZZ opened at $167.29 on Tuesday. The stock has a market cap of $10.16 billion, a P/E ratio of -27.56, a PEG ratio of 0.89 and a beta of 0.26. The company’s fifty day simple moving average is $168.84 and its 200-day simple moving average is $144.30. The company has a current ratio of 1.65, a quick ratio of 1.44 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals has a 52 week low of $95.49 and a 52 week high of $182.99.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Kennedy Capital Management LLC purchased a new stake in shares of Jazz Pharmaceuticals in the second quarter valued at $1,100,000. Wedge Capital Management L L P NC purchased a new position in shares of Jazz Pharmaceuticals during the third quarter valued at $27,834,000. Sequoia Financial Advisors LLC purchased a new stake in Jazz Pharmaceuticals in the 3rd quarter worth about $605,000. Measured Wealth Private Client Group LLC boosted its position in Jazz Pharmaceuticals by 47.1% during the 2nd quarter. Measured Wealth Private Client Group LLC now owns 4,855 shares of the specialty pharmaceutical company’s stock worth $515,000 after acquiring an additional 1,554 shares during the period. Finally, Schroder Investment Management Group grew its stake in Jazz Pharmaceuticals by 90.1% during the 2nd quarter. Schroder Investment Management Group now owns 17,816 shares of the specialty pharmaceutical company’s stock valued at $1,891,000 after acquiring an additional 8,444 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $171.20, for a total value of $797,792.00. Following the transaction, the chief accounting officer owned 7,012 shares in the company, valued at approximately $1,200,454.40. The trade was a 39.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total value of $379,363.38. Following the sale, the senior vice president directly owned 19,508 shares of the company’s stock, valued at approximately $3,306,801.08. This represents a 10.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 123,791 shares of company stock worth $21,991,850 in the last ninety days. Insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.